Cargando…

Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen

PURPOSE: Recent data have shown that the expression levels of long noncoding RNAs (lncRNAs) are associated with tamoxifen sensitivity in estrogen receptor (ER)-positive breast cancer. Herein, we constructed an lncRNA-based model to predict disease outcomes of ER-positive breast cancer patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Gen, Chen, Xiaosong, Liang, Yue, Wang, Wei, Fang, Yan, Shen, Kunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158153/ https://www.ncbi.nlm.nih.gov/pubmed/30275856 http://dx.doi.org/10.4048/jbc.2018.21.e39

Ejemplares similares

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer()
por: Wang, Gen, et al.
Publicado: (2017)

A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen
por: Wang, Kang, et al.
Publicado: (2018)

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
por: Li, Shuai, et al.
Publicado: (2020)

Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer
por: Sun, Xi, et al.
Publicado: (2021)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

Prognostic significance of autophagy related genes in estrogen receptor positive tamoxifen treated breast cancer
por: Mishra, Alok, et al.
Publicado: (2020)

Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer
por: Wang, Yanyan, et al.
Publicado: (2021)

Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
por: Gao, Pin, et al.
Publicado: (2018)

Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients
por: Mullooly, Maeve, et al.
Publicado: (2019)

Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs
por: Cheng, Ran, et al.
Publicado: (2020)

Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG Study
por: Lyng, Maria B., et al.
Publicado: (2013)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
por: Cheng, Shujie, et al.
Publicado: (2017)

Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
por: KIM, JINKYOUNG, et al.
Publicado: (2016)

Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines
por: Kim, Yun Gyoung, et al.
Publicado: (2019)

Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer
por: Boustan, Arad, et al.
Publicado: (2021)

Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
por: Han, Wonshik, et al.
Publicado: (2006)

The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration
por: Djahansouzi, Sirus, et al.
Publicado: (2021)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients
por: Yang, Li-Heng, et al.
Publicado: (2012)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer
por: Watanabe, Takayuki, et al.
Publicado: (2021)

MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers
por: Barwal, Tushar Singh, et al.
Publicado: (2021)

Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
por: Yu, Jing, et al.
Publicado: (2021)

Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells
por: Stella, Stefania, et al.
Publicado: (2023)

Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel, Nelson, et al.
Publicado: (2017)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy
por: Wang, Ji, et al.
Publicado: (2019)

Association of TGF-β(1) expression with the effects of tamoxifen on estrogen receptor positive and negative breast cancer cells
por: Perry, Roger R, et al.
Publicado: (1996)

miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer
por: HE, YUE-JUN, et al.
Publicado: (2013)

FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer
por: Wang, Jinhua, et al.
Publicado: (2016)

CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
por: Moon, Yong Wha, et al.
Publicado: (2017)

Dormancy Signatures and Metastasis in Estrogen Receptor Positive and Negative Breast Cancer
por: Kim, Ryung S., et al.
Publicado: (2012)

Identification of Gene Expression Signature in Estrogen Receptor Positive Breast Carcinoma
por: Thakkar, Arvind D., et al.
Publicado: (2010)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_af4dhnf4a6g5efnlsp5ti8hgrj